Manke Isaac 4

What Happened
Manke Isaac, a director of Q32 Bio Inc. (QTTB), was granted a derivative award on June 12, 2026 covering 9,810 shares. The Form 4 filed June 16, 2026 lists the transaction as an award/grant (code A) with a transaction price of $0.00 — i.e., no cash was paid at grant. This was a grant of an option-like award (derivative), not an immediate purchase or sale of common stock.

Key Details

• Transaction date: 2026-06-12; Form 4 filed: 2026-06-16 (timely filing).
• Transaction type: Award/Grant (derivative) for 9,810 shares; transaction price shown as $0.00.
• Vesting/exercise term (Footnote F1): The shares underlying this option vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the issuer's next annual meeting of stockholders, subject to the reporting person’s continued service.
• Shares owned after transaction: Not disclosed in the provided excerpt.
• No exercise or sale occurred at grant; no 10b5-1 plan, tax withholding, or late filing noted in the provided data.

Context
This was a compensatory option grant to a director. As a derivative award, it gives the holder the right to acquire shares in the future once vested and exercised; there is no immediate transfer of common shares or proceeds. Director option awards are common corporate compensation and do not by themselves indicate the director bought or sold stock. The filing does not show the exercise price; that detail would appear elsewhere in the full filing if disclosed.